Rockefeller Capital Management’s Viridian Therapeutics VRDN Stock Holding History
Bought
Maintained
Sold
Other funds holding VRDN
KCM
Rockefeller Capital Management's VRDN Position: Q3 2026 in Review
Rockefeller Capital Management increased its Viridian Therapeutics (VRDN) stake by 18% in Q3 2026, buying an estimated $1.22K and bringing the position to 370 shares worth $7.62K. The position accounts for ﹤0.01% of the portfolio, ranked #4265.
Rockefeller Capital Management first reported a position in VRDN in Q3 2025 and has held it in 5 quarters since. The position peaked at $35.9K in Q4 2025. 235 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.
- Rockefeller Capital Management held 370 shares of Viridian Therapeutics worth $7.62K as of Q3 2026.
- Rockefeller Capital Management bought 57 Viridian Therapeutics shares in Q3 2026, an estimated $1.22K.
- Viridian Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #4265 holding.
- Rockefeller Capital Management first reported a position in Viridian Therapeutics in Q3 2025 and has held it in 5 quarters since.
- Rockefeller Capital Management's Viridian Therapeutics position peaked at $35.9K in Q4 2025.
- 235 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.
Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.